



European Certificate in Medical Genetics and Genomics (ECMGG)*

UEMS[†] Section of Medical Genetics (UEMS-SMG)

in collaboration with

the Branch of Medical Geneticists of the European Board for Medical Genetics
(EBMG-BMG)

& the European Society of Human Genetics (ESHG)

September 2023

The Rules, Description and Protocol of the ECMGG Examination 2024 (Online)

* *The specialty has different names in different countries, see EU document (EU) 2016/790, January 13 2016, and changes in attachment V, Directive 2005/36/EG. In this document, the specialty may also be referred to as 'Clinical Genetics'.*

[†] *Union Européenne des Médecins Spécialistes (European Union of Medical Specialists)*

CONTENTS

	Page
1. GENERAL BACKGROUND	3
2. WHY TAKE A EUROPEAN EXAMINATION IN MEDICAL GENETICS AND GENOMICS?	4
3. ELIGIBILITY CRITERIA – ECMGG	5
4. APPLICATION FOR THE EXAMINATION	6
5. EXAMINATION ADMISSION FEE (EUROS)	7
6. THE EXAMINATION STRUCTURE AND CONTENT	7
7. EXAMINATION OUTCOME	10
8. THE EXAMINATION COMMITTEE	11
9. INDEPENDENT ASSESSORS	12
10. EXAMINERS	12
11. ECMGG EXAMINATION BOARD	12
12. EXAMINATION SCHEDULE – ECMGG 2024	14
13. APPEALS PROCESS	15

1. GENERAL BACKGROUND

- 1.1 The European Certificate in Medical Genetics and Genomics (ECMGG), formerly a Diploma in 2019 (EDMGG), is a joint development of the UEMS Section of Medical Genetics (UEMS-SMG), the European Board for Medical Genetics (EBMG), and the European Society of Human Genetics (ESHG). It is intended to be the main knowledge-based assessment tool for Clinical/Medical Genetics and Genomics training in Europe, with the aim of establishing standards in the specialty to world class levels throughout all European countries.
- 1.2 The examination is overseen and supervised by the Examination Committee for the ECMGG of the UEMS-SMG and EBMG-BMG, and is also observed by representative(s) of the European Society of Human Genetics. The EBMG is the umbrella organization in Europe concerned with professional standards relating to the professionals that jointly deliver medical genetic services throughout Europe, namely Medical Geneticists, Genetic Counsellors/Nurses, and Clinical Laboratory Geneticists. The examination is also open to observation by central UEMS officials as appropriate.
- 1.3 The ECMGG 2024 is a two-part examination; it is scheduled for **April 26th, 2024** for the **Multiple-Choice Question (MCQ)** part, and for **June 17th, 2024** for the 2nd part, the **Structured Oral Assessment (SOA)**. The ECMGG is open to candidates worldwide, including trainees and fully trained Medical Geneticists, but for logistic reasons, candidate numbers will be provisionally limited to **60**. Registration for the ECMGG 2024 will open on October 1st, 2023 and will close January 31st, 2024 (<https://www.uems-ecmgg.org/Apply.html>). Candidates *must* be medical graduates to sit the ECMGG, i.e. it is not open to non-medical geneticists. Candidates from UEMS members countries will be given initial priority (see Section 12).
- 1.4 No post-nominals accompany the ECMGG but the certification is valid for life. It will be valid for practice only in countries where it is ratified and recognized as an official certificate for this purpose.
- 1.5 The UEMS promotes continuing good medical practice through Continuing Medical Education and Continuing Professional Development (CME/CPD) systems and certification. This is strongly recommended for active practitioners; indeed, in many countries it is mandatory through official bodies at national level, usually conducted by a recurring process of record review and appraisal.

2. WHY TAKE A EUROPEAN EXAMINATION IN MEDICAL GENETICS AND GENOMICS?

- 2.1 The UEMS is striving to harmonize higher medical training across the nations of Europe in order to raise standards to world-class levels equitably across its member states, and indeed beyond. This, in turn, is aimed at translation into the highest standards of health care service delivery equitably across European nation states.
- 2.2 In the field of Clinical / Medical / Human Genetics and Genomics, the ECMGG thus represents a significant step towards the raising of standards in this specialty across Europe, with the improvement and equitable provision of services that are currently very varied across Europe. It is anticipated this will contribute to the global mobility of specialists in Clinical / Medical / Human Genetics and Genomics.
- 2.3 To achieve a 'Pass' in the ECMGG examination is an indication that the candidate has a suitable knowledge base to practice as a Medical Geneticist. However, certification at this level does not in itself equate to having sufficient competencies and/or experience to practice Medical Genetics at senior (consultant) level. Appointment at senior level is subject to formal criteria, established by each nation's official medical regulatory authorities, which may or may not include recognition of the ECMGG.
- 2.4 Recognition of the ECMGG throughout European nations will be sought by the UEMS and the EBMG, something that has already been achieved for several other medical specialties with respect to their equivalent European-wide examinations. The aim is that certification will form a significant part of the candidate's fitness to practice, wherever they seek employment, recognizing that it is primarily the knowledge base that is being assessed. Indeed, it is intended to be a mark of excellence in knowledge.
- 2.5 Taking and passing the examination should be an indication of commitment to career-long learning, combined with a continuing record of CME. Skills and attitudes (*or* professionalism), the other essential components and qualities for fully trained practitioners, can only be adequately assessed through continuous clinic-based supervision and evaluation, together with evidence of the ability to work collaboratively in teams. The oral part of this examination aims to partially assess some of these skills and attitudes.

3. ELIGIBILITY CRITERIA (ECMGG)

- 3.1 The examination has been designed to be suitable for trainees in the late stages of their training, i.e. in the year prior to being appointed as a fully trained Medical Geneticist. However, anyone with a *bona fide* medical qualification may take the exam subject to payment of the Admission (examination) Fee. Therefore, individuals are eligible to sit the ECMGG examination if they have a medical qualification (MD, or in some countries MB ChB/BS).
- 3.2 Proof of eligibility must be provided with the application by attachment of a notarized copy of the candidate's medical qualification (or specialist diploma / certificate in the case of senior doctors). On the day of the examination, only personal documents with photographic identification are required (e.g. passport or national identification card).
- 3.3 Any individual found to be canvassing Examination Committee members for confidential information relating to any aspect of the examination will be disqualified from sitting the examination, and may forfeit their Admission Fee if this has already been paid.
- 3.4 Any individual who has received the ECMGG Certificate but was found to have used any unfair means to achieve their result will have their certificate revoked.

4. APPLICATION FOR THE EXAMINATION

- 4.1 When applying to sit the ECMGG, candidates will declare their consent to taking the examination in the established format and structure, and acknowledge that cancellations are only possible in accordance with the rulings of the cancellation policy.
- 4.2 An application form must be completed and submitted by **January 31st, 2024**. For logistic reasons the number of candidates for the ECMGG 2024 will provisionally be limited to **60**, and if necessary, priority will be given to candidates from UEMS member nations.
- 4.3 **Important:** Personal details must be correctly submitted, including full name, as the data requested will be used for the certificates. The Admission Fee in Euros and contact details for informing about the result must accompany the application. A notarized (scanned or photographed) copy of the candidate's medical qualification should be sent as early as possible, and no later than February 6th, 2024. Receipt of the medical qualification will be acknowledged and the candidate informed after it has been checked (if the medical qualification is written in a language not known to the review team, the candidate may be asked to provide a notarized official translation). The Admission Fee has to be paid by bank transfer (see bank details below), as payment by credit card is not possible. The Admission Fee from all candidates must be received by February 29th, 2024. The date of transfer of the fee to the UEMS Section of Medical Genetics bank account will serve as the application date. Candidates from countries whose currency is not the EURO must pay the currency exchange fee in addition to the Admission Fee.
- 4.4 The bank details are as follows:
- | | |
|-----------------|---|
| Account name: | UEMS /S. CLINICAL GENETICS |
| Account number: | 001-6762413-37 |
| IBAN code: | BE35 0016 7624 1337 |
| BIC code: | GEBABEBB |
| Bank address: | BNP Paribas Fortis
Montagne du Parc 3
1000 Brussels |
- 4.5 In order to comply with Belgian Law, please follow this procedure regarding the title of transfer:
- Please include the title of transfer:
"EXAM – THE NAME OF EXAMINEE / CANDIDATE – COUNTRY"
 - Please do not refer to 'payment' or 'invoice'
- 4.6 For registered candidates who have paid their Admission Fee, more details about the online process and procedure will be sent in the weeks prior to the exam and a briefing with the necessary technical details for each part of the examination will be scheduled.
- 4.7. For candidates who have paid their Admission Fee and are registered, a receipted invoice will be available upon request.

5. EXAMINATION ADMISSION FEE (EUROS):

- 5.1 The Admission Fee is given below. It applies for 2024 and is reviewed annually. Additional fees may apply in the event of irregularities that require further administrative work.
- 5.2 The Admission Fee includes the fees for both parts of the ECMGG, i.e. the written (MCQ) and the oral (SOA) part. The fee has to be fully paid by all candidates, including those who do not proceed to the oral part.
- 5.3 In the event of cancellations prior to 28 days preceding the first part of the examination, an application for a subsequent examination will be possible for the same fee. Cancellations less than 28 days prior to the examination (i.e. after **March 29th, 2024**) will not qualify for the same fee at a subsequent sitting (see also paragraph 7.7).
- 5.4 Examination Admission Fee for 2024: **600 €**

6. THE EXAMINATION STRUCTURE AND CONTENT

- 6.1 The examination is primarily a knowledge-based assessment, based on the European Training Requirement (ETR) curriculum and syllabus for Clinical/Medical Genetics and Genomics (<https://www.uems-ecmgg.org/Moreinfo.html>), but also seeks to partially assess skills and attitudes (professionalism) relevant for Clinical/Medical Genetics and Genomics with respect to clinical reasoning, problem-solving, communication, and ethics. This is consistent with the roles promoted by UEMS, namely Medical Expert, Communicator, Scholar, Health Advocate, and Professional.
- 6.2 The examination will consist of two distinct parts: a **Multiple-Choice Questions** (MCQ) part and a **Structured Oral Assessments** (SOA) part. The **MCQ part** will be delivered virtually on **April 26th, 2024**, in partnership with a commercial company (CYIM, France) which will provide online live proctoring via a commercial provider (ProctorU). The **SOA part** of the exam will also take place virtually on **June 17th, 2024**, via CYIM.
- 6.3 Candidates *must* pass the MCQ part in order to advance to the SOA part of the exam. No access to material on the internet or literature resources will be permitted during the exam.
- 6.4 The language of both parts of the examination is *English*. The English language vocabulary and structure of the MCQ is kept as simple as possible, and some allowance is made in the oral exam for candidates whose English is relatively limited.
- 6.5 **MCQ part: 110 multiple-choice questions; time allowed: 2¾ hours (165 minutes)**
 - i. 110 individual questions will test knowledge based on the UEMS SMG-Guidelines and the Syllabus in Medical Genetics (<https://www.uems-ecmgg.org/Moreinfo.html>). The questions are written, rigorously reviewed, and selected by the Examination Committee. They are then assessed by a panel of independent reviewers before being included in the final version of the examination paper. In this way, *standard setting* of the MCQs will have been undertaken according to the Angoff rank ordering method.

- ii. Candidates should take the examination from a private location using a computer with a reliable connection to internet. It is each candidate's responsibility to provide their own computer and identify a location with reliable internet access and secure connection. For technical reasons it is strongly discouraged to use hospital or institutional internal networks; similarly, hospital or institutional computers / laptops should not be used because they may have security software which thwarts connection to the examination platform. Thus, candidates should have full administrative rights for their computers / laptops regarding uploading and deleting of software programmes.
- iii. During the weeks prior to the MCQ part, opportunities for technical checks for each candidate and information about the process of the exam will be provided, in cooperation with the commercial provider. Candidates should take advantage of these opportunities.
- iv. The format of the MCQs is a brief *scenario* (usually *clinical*), with or without *investigations* (*data, test results*), followed by the *question*. Some questions include an image. Five possible answers are provided, one of which is the *best correct answer*. The answers appear in alphabetical or logical order in all questions.
- v. Some answer options are definitely wrong whilst some are correct but not as good as the best correct one.
- vi. The candidate should therefore select one of the five answers that they consider the *best correct answer*. It will not be possible to select more than one answer. There is no penalty (negative mark) for a wrong answer.
- vii. The outcomes of the MCQ part will be subjected to rigorous statistical analysis in parallel with the Angoff analysis undertaken as part of the standard setting process. The results of the MCQ part of the exam will be finally adopted at an Interim Examination Board Meeting within 3 weeks of the sitting.
- viii. An anonymised online survey is sent out to candidates within a week of the MCQ part of the exam in order to collect feedback on the process.
- ix. Candidates will be notified of the outcome of the MCQ exam within 3 weeks of the sitting. The candidate's percentage achieved, and the percentage required to advance to the SOA part of the exam, will be given with the notification.
- x. Here is a sample question, and more sample questions are available at:
<https://uems-genetics.org/Exam.html> and
<https://www.uems-ecmgg.org/Examination.html>

6.6 **SOA part: 6 stations; 10 minutes per station**

- i. Only candidates who pass the MCQ part will advance to the SOA part of the exam.
- ii. The SOA scenarios and questions are written, rigorously reviewed, and selected by the Examination Committee. The SOA exam is standard set using the Hofstee process, with parameters agreed by consensus of a panel of at least 4 senior clinical geneticists from a minimum of 3 UEMS countries.

- iii. The SOA part of the exam will be conducted in *English*. The examiners are all aware that competence in the English language varies between candidates and proficiency in English is not part of the assessment. Allowance will be made for different levels of English as far as possible, and every effort will be made to minimise language difficulties for candidates.
- iv. It is each candidate’s responsibility to provide their own computer and identify a location with reliable internet access and secure connection (as provided by CYIM). For technical reasons it is strongly discouraged to use hospital or institutional internal networks. The online platform for the oral exam is likely to be Zoom.
- v. The SOA part of the exam consists of 6 OSCE (Objective Structured Clinical Examination)-style stations to be visited by all candidates. At each station, the candidate will be shown a screen describing a clinical case. This will be one page that may contain a clinical scenario, family tree, and/or genetic test results. The candidate will be invited to read the clinical scenario during a period of 2 minutes. They will then be asked a standardized set of questions over 8 minutes. After completing the questions at each respective station, the candidates will move to the next station.
- vi. Each station will have 3 questions testing each of the following 3 domains: (a) Application of Genetic Principles; (b) Clinical Communication and Counselling Skills; and (c) Clinical, Ethical, and Legal Aspects.
- vii. Each station will have 2 examiners, who may be external examiners or members of the Examination Committee. In addition, an observer may be present who does not interfere with the examination process.
- viii. Each candidate will be asked the standardized set of questions by one examiner while the other examiner takes notes. The two examiners will independently score the candidate on each of the 3 domains, on a 4-point scale: (4) Clear Pass; (3) Borderline Pass; (2) Borderline Fail; and (1) Clear Fail; this generates 6 data points per candidate per station.

The following grid describes the marking system and the domains to be assessed:

Candidate #	Mark	(a) Application of Genetic Principles	(b) Clinical Communication and Counselling Skills	(c) Clinical, Ethical, and Legal Aspects
Clear Pass	4			
Borderline Pass	3			
Borderline Fail	2			
Clear Fail	1			

- ix. The aims of the SOA format are to standardise the oral assessment process and minimize presentation differences between candidates.
- x. The outcomes of the SOA part of the exam will be subjected to statistical analysis.
- xi. An anonymised online survey is sent out to candidates within a week of the SOA part of the exam to collect feedback on the process.
- xii. The results of the SOA part of the exam will be finally adopted at a Final Examination Board Meeting within 3 weeks of the sitting.
- xiii. Candidates will be notified of their result within 3 weeks from the exam sitting.
- xiv. An example scenario and questions will be available at:
<https://uems-genetics.org/Exam.html> and
<https://www.uems-ecmgs.org/Examination.html>

6.7 As both elements of the exam are conducted online, a candidate may encounter technical difficulties during the the exam. We work very hard to minimise this risk.

- i. MCQ exam. If a candidate is disconnected, or loses time during the exam for technical reasons, their exam duration will be extended to replace the time lost during disconnection. In the case of other technical difficulties, at the discretion of the exam committee, advice may be taken from our statistical expert as to whether any further adjustment should be made. If a candidate is completely unable to take the exam for technical reasons, despite having undergone the routine system checks and complying with all requirements, then they will be offered the opportunity to resit the exam without additional charge at the next sitting.
- ii. SOA exam. Difficulties may be experienced with internet connection during a station of the exam. In this case the candidate will be offered the opportunity to resit the individual station during the exam process. If more significant difficulties arise, the candidate will be fitted into a subsequent circuit of the exam on the same day.

7. EXAMINATION OUTCOME

- 7.1 In registering for the examination, the candidate should accept that the result of the examination is final. A legal debate on the final decision is not possible. However, in exceptional circumstances a formal Appeal will be managed according to the process described in Section 13 (Appeals process).
- 7.2 The pass mark will be calculated with help of an Angoff rank ordering evaluation as a control measurement, and other statistical methods provided by a professional statistician with experience in examination methodology and analysis.
- 7.3 External, independent assessors may be appointed by the Examination Committee to advise and oversee fairness in the final allocation of marks, or as part of the Appeals process if appropriate.
- 7.4 In order to achieve an overall pass, candidates should achieve a 'Pass' in *both* parts of the examination.

- 7.5 Some feedback will be available, for unsuccessful candidates only, after the Oral exam, once the comments of all examiners have been collated. Appealing the final decision is covered in the Appeals Process, Section 13. Feedback from the MCQ exam will not be provided.
- 7.6 If a candidate does not achieve the pass mark, they may re-sit the examination at a later date, subject to payment of the corresponding Admission Fee. If a 'Pass' is only achieved in the MCQ paper but not the SOA exam, both parts of the examination will have to be taken in a following sitting.
- 7.7 If a candidate falls ill for one or both parts of the examination, a medical attestation is expected. In case of a medical attestation, the candidate will be permitted to carry over the paid admission fee to a following sitting of the examination.
- 7.8 Successful candidates will be issued with an electronic certificate to mark their achievement. Their names and nationality will be added to UEMS-SMG website, subject to the candidate's consent in writing.

8. THE EXAMINATION COMMITTEE (EC)

- 8.1 The remit of the EC is to design the examination, write, review and select questions, establish a standard setting process and quality control measures, identify independent assessors and examiners, and organize the examination.
- 8.2 The EC organizes the question-writing examination group, which comprises ~20 individuals (<https://uems-genetics.org/ExaminationGroup.html> and <https://www.uems-ecmagg.org/Moreinfo.html>), many of whom are National Delegates to the UEMS Section of Medical Genetics. Some members have been invited to join because of their acknowledged expertise in examination methodology. At the time of writing, 15 European nations are represented on the group, covering all regions of Europe. The large majority of members are experienced Medical Genetics, and in addition the committee accommodates high achieving, committed colleagues who have recently completed their training. In exceptional circumstances a member of another genetic profession, eg a Clinical Laboratory Geneticist, may be co-opted to the EC to assist with question writing.
- 8.3 The EC writes MCQs and constructs SOAs for the ECMGG, and edits MCQs submitted voluntarily from other sources.
- 8.4 All members of the EC have pledged strict confidentiality in relation to question material, having signed an official Declaration of Confidentiality. Any member of the group found to have divulged information inappropriately, i.e. broken confidentiality, will have their membership terminated with immediate effect.

9. INDEPENDENT ASSESSORS

- 9.1 Experienced Medical Geneticists, independent of the EC, are recruited to undertake a review of the MCQs in advance of the examination itself, a standard-setting process leading to an Angoff rank ordering evaluation. In 2023, this group comprised 15 individuals, representing 8 European nations.
- 9.2 These assessors are required to pledge their confidentiality in relation to all examination material, and will have signed an official Declaration of Confidentiality.

10. EXAMINERS

- 10.1 A panel of independent, external examiners will be recruited, principally to participate in the SOA part of the examination. It is intended that each SOA question will have a minimum of one external examiner, although this may not always be possible.
- 10.2 The minimum criteria for appointment as an external examiner are as follows:
- i. Their national specialist organisation is a member of the UEMS-SMG.
 - ii. Medically qualified as a Medical Geneticist with a minimum of 5 years' clinical experience after specialisation.

In addition, it is desirable that they have previous examination experience. A mandatory briefing for oral examiners takes place 1-2 weeks prior to the SOA part of the examination.

- 10.3 Examiners are required to pledge their confidentiality in relation to all examination material, and will have signed an official Declaration of Confidentiality.
- 10.4 Recognizing that a conflict of interest may arise between examiner(s) and candidate(s), prior to the examination, examiners will be shown a list of candidates. In the event of any conflict of interest being expressed, every effort will be made to ensure that a candidate is not actively examined by the examiner with whom there is a real or perceived conflict.

11. ECMGG EXAMINATION BOARD

- 11.1 Within 3 weeks following the MCQ part of the exam, and after statistical analysis has been completed, the Chair of the Examination Committee will convene an *Interim* Examination Board Meeting to adopt the results and determine those candidates who are permitted to progress to the Oral part of the exam. The membership of the Examination Board comprises SMG Bureau members and members of the Examination Committee; in addition, members of the Standard-Setting Group will be invited to attend.
- 11.2 Within 3 weeks following the Oral part of the exam, and after statistical analysis has been completed, the Chair of the Examination Committee will convene a *Final* Examination Board Meeting to adopt the final results and determine those candidates who have passed, and can thus be awarded the ECMGG Certificate. The membership of the Examination Board comprises

SMG Bureau members, members of the Examination Committee, and representatives of the external examiners for the Oral part; in addition, members of the Standard-Setting Group will be invited to attend. As with others involved with any aspect of the examination, all individuals will have signed an official Declaration of Confidentiality.

12. EXAMINATION SCHEDULE, ECMGG 2024

This schedule may be subject to minor changes.

October 1, 2023	Registration opens. Prospective candidates notify their 'Expression of Interest' to sit the exam. Priority application for UEMS member countries will be processed during October-November. From December 1 st <i>all</i> candidates will be processed.	Acknowledgement sent within 5 working days
November – December 2023	Examination questions reviewed and finalised	
January – February 2024	MCQ paper sent to independent standard-setters	
January 31, 2024	Registration closes	
February 6, 2024	Final date for receiving notarised copy of the candidate's medical qualification	Acknowledgement sent within 5 working days
February 29, 2024	Final date for receiving candidate's examination fee	Acknowledgement sent within 5 working days
March 29, 2024	Last date for candidate cancellation to ensure full refund of examination fee	
April 15-24, 2024	Period of trial connection to exam platform and exam briefing (virtual)	Exact dates to be confirmed
April 26, 2024	MCQ PAPER	
May 17, 2024	Final date for notifying candidates of their results of the MCQ paper	Attempts will be made to notify candidates earlier
June 10-14, 2024	Period of SOA (oral) exam briefing (virtual)	Exact dates to be confirmed
June 17, 2024	ORAL EXAMINATION	
July 8, 2024	Final date for notifying candidates of their results of the oral exam	Attempts will be made to notify candidates earlier

13. APPEALS PROCESS

13.1 The UEMS has published a document entitled: 'UEMS-CESMA GUIDELINE ON APPEAL PROCEDURES FOR EUROPEAN POSTGRADUATE MEDICAL ASSESSMENTS'

https://www.uems.eu/_data/assets/pdf_file/0004/28219/UEMS-2015.36-UEMS-CESMA-Guideline-on-appeal-amended-after-council-meeting.pdf

Thus, the UEMS Section of Medical Genetics closely follows the guidance laid out in this document with respect to an Appeal in the case of the ECMGG.

13.2 As stated in the UEMS document cited, the grounds for an Appeal are: „*limited to procedural irregularity, examiner misconduct, administrative errors or extenuating circumstances that have adversely affected the candidate's performance. Any illness affecting performance must be declared at the time, and supported by a timely medical certificate (supplied within five working days).*” Grounds for an Appeal include potential underlying discrimination issues such as gender, race or language. An Appeal is also valid if it is perceived that there is a poor match between the balance of the assessment questions and the curriculum or syllabus.

However, „*processes can be challenged, while the judgement of performance of candidates cannot be challenged.*”

13.3 For candidates who have not achieved the pass mark, feedback can be given (paragraph 7.5). This feedback will consist of a brief description of the standard-setting process, statistical analysis of results, and (in the case of the oral exam) a summary of the examiners' written comments. If, having received this feedback, the candidate wishes to launch a formal Appeal, with respect to either MCQ or SOA sittings, they must submit a formal request in writing within 15 days of receiving their feedback from the Examination Committee.

13.4 The candidate's formal Appeal must be submitted in the language of the exam (English) and should include:

- Reason(s) for making the Appeal
- Reason(s) why the feedback information already provided did not adequately deal with the complaint
- Naming of the examination officer(s) implicated in the complaint (if appropriate)

The Appeal should be submitted to the President of the UEMS Section of Medical Genetics, the Chair of the Examination Committee, and, if desired, copied to the UEMS central administration in Brussels.

13.5 The fee for an Appeal is €200 and should be made concurrently with the submission. The fee is required to cover the cost of establishing a Hearing with an Appeal Panel, and if this does not take place the fee may be partially or fully refunded.

13.6 Having received the formal Appeal from the candidate, examination officers may (if appropriate) provide further detailed feedback relating to the standard-setting process, statistical analysis of results, and (in the case of the oral exam) examiners' original written comments. Where (an) examiner(s) has/have been named, they may be asked to provide a statement for the Appellant.

If these measures do not satisfy the Appellant such that the Appeal is withdrawn, the process will go forward to a Hearing with an Appeal Panel.

13.7 The Appeal Panel and Hearing will be convened as soon as reasonably possible at a mutually convenient time, and will most likely take place as a virtual meeting. The Panel will comprise a minimum of 3 persons:

- The President of the Section of Medical Genetics (unless named in the complaint)
- An examiner who did not examine the Appellant (and is not named in the complaint)
- A medically qualified member of the Board of the European Society of Human Genetics (it could be the President); this Panel member is completely independent of the examination; this person will likely be Chair of the Panel
- An additional independent person if deemed necessary, e.g. a UEMS officer from a different section who has experience with European postgraduate exams

The Panel will appoint one of its members to record the minutes.

The Appellant has the freedom to be accompanied by a relative or friend, providing support, who might also assist with translation if necessary.

13.8 All the relevant documentation relating to the Appeal will be circulated to the Panel and Appellant at least 10 working days prior to the Hearing. The language of the Hearing is English, i.e. the same as that of the examination.

13.9 The appointed Chair of the Hearing will set the date for the event, ensuring that adequate time is available to receive the Appellant's case and fully discuss the issues raised. The Chair will set the terms of the Hearing, the agenda, and conduct, seeking to deal with the claims and arguments factually and truthfully, and free of coercion and emotion.

13.10 When the agenda of the Hearing has been concluded the Appellant will withdraw, having been informed of the likely time and manner by which the decision of the Panel will be communicated. The Panel will continue the meeting to deliberate on the case and reach a decision. The majority opinion will be adopted, with the decision of the Chair being the deciding vote if necessary.

13.11 Outcome

The Appeal having proceeded to a Hearing, one of three outcomes is possible:

- i. *Appeal dismissed*, examination results confirmed, and no reimbursement of the Appeal fee.
- ii. *Appeal partially upheld*, indicating that the Appeal was valid but the grounds were insufficient to influence the examination result, which is formally confirmed. In this event 50% of the Appeal fee will be credited towards another sitting of the examination by the candidate.
- iii. *Appeal fully upheld*, indicating that the candidate's results will be declared null and void. No charge will be levied to the candidate for the next attempt at the examination, and the Appeal fee will be refunded in full.